CNP 015

Drug Profile

CNP 015

Alternative Names: GT 015

Latest Information Update: 13 Feb 2006

Price : $50

At a glance

  • Originator Nonindustrial source; Queens University
  • Developer Nonindustrial source; Vernalis
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myocardial infarction; Neuroprotection

Most Recent Events

  • 13 Feb 2006 No development reported - Preclinical for Neuroprotection in Canada (unspecified route)
  • 13 Feb 2006 No development reported - Preclinical for Myocardial infarction in Canada (unspecified route)
  • 14 Dec 2005 Cita-NeuroPharmaceuticals has been acquired and merged into Vernalis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top